Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking EPA milestones, cash burn, or insider confidence around SenesTech’s game-changing fertility control for rats often means sifting through dense biotechnology disclosures. Our platform solves that problem immediately. Stock Titan’s AI reads every SenesTech SEC filing the moment it hits EDGAR and translates regulatory jargon into plain language summaries, so you see the impact on ContraPest and Evolve without spending hours decoding footnotes.
Need the SenesTech quarterly earnings report 10-Q filing to gauge sales traction? Curious about a sudden share spike and want SenesTech insider trading Form 4 transactions in real time? Each document—10-K, 10-Q, 8-K, DEF 14A—appears seconds after release, paired with AI-powered highlights that surface R&D expense trends, distributor contract details, and environmental compliance data. Investors often ask, “How do I read the SenesTech annual report 10-K simplified?” or “Where are SenesTech executive stock transactions Form 4 listed?” The answers are one click away, with pop-up explanations and side-by-side metric tracking.
Whether you’re monitoring SenesTech proxy statement executive compensation, comparing revenue guidance across quarters, or reviewing an unexpected SenesTech 8-K material events explained, our coverage stays comprehensive. AI extracts key numbers, flags material risks, and even links related SenesTech earnings report filing analysis. Use the dashboard to set alerts for SenesTech Form 4 insider transactions real-time or get bite-size notes for understanding SenesTech SEC documents with AI. Complex biotech filings, made clear, so you spend less time reading and more time making informed decisions.
SenesTech has announced an At The Market (ATM) offering of up to $843,069 of common stock through H.C. Wainwright & Co. The offering will be conducted on the Nasdaq Capital Market (SNES) at prevailing market prices, with Wainwright receiving a 3.0% commission on gross sales.
Key details of the offering:
- Last reported stock price: $3.96 per share (June 20, 2025)
- Current market cap (non-affiliate): $8.56 million based on 2,015,291 shares
- Previous sales under Form S-3: $2,011,926.24 in past 12 months
The company specializes in fertility control products for pest management, with two main product lines: ContraPest and Evolve. Recent developments include the January 2024 launch of Evolve Rat and May 2024 launch of Evolve Mouse, both classified as minimum risk pesticides. ContraPest is registered in all 50 states, while Evolve Rat is authorized in 48 states and Evolve Mouse in 36 states.
SenesTech has filed a prospectus for the resale of up to 1,517,608 shares of common stock, comprising 1,498,872 Inducement Shares (exercise price $2.90) and 18,736 Placement Agent Shares (exercise price $3.625). The shares are issuable upon exercise of outstanding warrants.
Key highlights:
- Trading on Nasdaq Capital Market under symbol SNES with last reported price of $3.40 (June 13, 2025)
- Company will receive proceeds from cash exercises of warrants but not from cashless exercises
- Selling stockholders bear selling expenses while company covers registration costs
SenesTech's business focuses on rodent population control through fertility management products ContraPest and Evolve. The company expects continued operating losses and faces risks including product commercialization challenges, market acceptance, and maintaining Nasdaq listing compliance. Forward-looking statements indicate plans for international expansion and using warrant proceeds for R&D, working capital, and potential strategic acquisitions.
The SEC has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 4:00 P.M. The registration statement was filed under file number 333-288097.
Form S-3 is a simplified security registration form used by companies that have already met certain reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their intended securities offering as outlined in the registration statement.
This development is significant for investors as it means:
- SenesTech can now legally begin selling the registered securities to the public
- The company has satisfied SEC review requirements
- The registration statement contains complete and accurate information according to SEC standards
The Securities and Exchange Commission has declared SenesTech's Form S-3 registration statement effective as of June 24, 2025, at 5:00 P.M. The registration statement was filed under file number 333-286955.
Form S-3 is a simplified security registration form used by companies that have already met specific reporting requirements. This effectiveness notice indicates that SenesTech can now proceed with their planned securities offering as outlined in the registration statement.
This is a significant development for SenesTech (SNES) as it:
- Allows the company to access the public markets for capital raising
- Provides flexibility to issue various types of securities
- Enables shelf offerings for up to three years from the effective date
FAQ
What is the current stock price of Senestech (SNES)?
What is the market cap of Senestech (SNES)?
What is the primary focus of SenesTech Inc?
What products does SenesTech offer?
How does SenesTech’s fertility control technology work?
How do SenesTech products integrate into pest management programs?
What are the advantages of non-lethal rodent control?
How does SenesTech ensure environmental and user safety?
What sets SenesTech apart from traditional pest control companies?
How does SenesTech contribute to sustainable urban environments?
